Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 463,100 shares, a growth of 483.2% from the January 31st total of 79,400 shares. Currently, 8.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is presently 0.2 days.
Bio-Path Trading Up 3.4 %
Shares of Bio-Path stock traded up $0.01 during trading hours on Thursday, hitting $0.19. The company had a trading volume of 187,572 shares, compared to its average volume of 1,607,767. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67. The company’s 50-day moving average is $0.82 and its two-hundred day moving average is $0.92.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Bio-Path in a research report on Saturday, February 22nd. They set a “sell” rating for the company.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- 3 Dividend Kings To Consider
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- ESG Stocks, What Investors Should Know
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
